

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ivermectin (0.50%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.02.2025
6.0	14.04.2025	10875044-00011	Date of first issue: 20.10.2022

---

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Ivermectin (0.50%) Liquid Formulation

Other means of identification : COOPERS PARAMAX POUR-ON FOR BEEF AND DAIRY CATTLE (50558)

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-stance/Mixture : Veterinary product

Recommended restrictions on use : Not applicable

#### 1.3 Details of the supplier of the safety data sheet

Company : MSD  
Kilsheelan  
Clonmel Tipperary, IE

Telephone : 353-51-601000

E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

#### 1.4 Emergency telephone number

+1-908-423-6000

---

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

##### Classification (REGULATION (EC) No 1272/2008)

Eye irritation, Category 2	H319: Causes serious eye irritation.
Skin sensitisation, Category 1	H317: May cause an allergic skin reaction.
Germ cell mutagenicity, Category 2	H341: Suspected of causing genetic defects.
Specific target organ toxicity - single exposure, Category 3	H336: May cause drowsiness or dizziness.
Short-term (acute) aquatic hazard, Category 1	H400: Very toxic to aquatic life.
Long-term (chronic) aquatic hazard, Category 1	H410: Very toxic to aquatic life with long lasting effects.

#### 2.2 Label elements

##### Labelling (REGULATION (EC) No 1272/2008)

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ivermectin (0.50%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.02.2025
6.0	14.04.2025	10875044-00011	Date of first issue: 20.10.2022

Hazard pictograms

:



Signal word

:

Warning

Hazard statements

:

H317 May cause an allergic skin reaction.  
H319 Causes serious eye irritation.  
H336 May cause drowsiness or dizziness.  
H341 Suspected of causing genetic defects.  
H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements

:

### Prevention:

P201 Obtain special instructions before use.  
P273 Avoid release to the environment.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

### Response:

P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.  
P308 + P313 IF exposed or concerned: Get medical advice/ attention.  
P391 Collect spillage.

Hazardous components which must be listed on the label:

Propan-2-ol

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures

#### Components

Chemical name	CAS-No.	Classification	Concentration
---------------	---------	----------------	---------------

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ivermectin (0.50%) Liquid Formulation

Version 6.0      Revision Date: 14.04.2025      SDS Number: 10875044-00011      Date of last issue: 04.02.2025  
Date of first issue: 20.10.2022

	EC-No. Index-No. Registration number		(% w/w)
Propan-2-ol	67-63-0 200-661-7 603-117-00-0	Flam. Liq. 2; H225 Eye Irrit. 2; H319 STOT SE 3; H336	$\geq 70 - < 90$
7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate	2386-87-0 219-207-4 607-773-00-9	Skin Sens. 1; H317 Muta. 2; H341 STOT RE 2; H373 (nasal cavity) Aquatic Chronic 3; H412	$\geq 1 - < 2,5$
Ivermectin	70288-86-7 274-536-0	Acute Tox. 2; H300 Acute Tox. 3; H311 STOT SE 1; H370 (Central nervous system) STOT RE 1; H372 (Central nervous system) Aquatic Acute 1; H400 Aquatic Chronic 1; H410  M-Factor (Acute aquatic toxicity): 10.000 M-Factor (Chronic aquatic toxicity): 10.000	$\geq 0,25 - < 1$

For explanation of abbreviations see section 16.

### SECTION 4: First aid measures

#### 4.1 Description of first aid measures

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with plenty of water.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ivermectin (0.50%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.02.2025
6.0	14.04.2025	10875044-00011	Date of first issue: 20.10.2022

Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.  
If easy to do, remove contact lens, if worn.  
Get medical attention.

If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.

### 4.2 Most important symptoms and effects, both acute and delayed

Risks : May cause an allergic skin reaction.  
Causes serious eye irritation.  
May cause drowsiness or dizziness.  
Suspected of causing genetic defects.

### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

## SECTION 5: Firefighting measures

### 5.1 Extinguishing media

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

### 5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ivermectin (0.50%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.02.2025
6.0	14.04.2025	10875044-00011	Date of first issue: 20.10.2022

Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

### SECTION 6: Accidental release measures

#### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

#### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g. by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

#### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

#### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

### SECTION 7: Handling and storage

#### 7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.  
Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.  
Advice on safe handling : Do not get on skin or clothing.  
Do not breathe mist or vapours.  
Do not swallow.  
Do not get in eyes.  
Wash skin thoroughly after handling.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ivermectin (0.50%) Liquid Formulation

Version 6.0      Revision Date: 14.04.2025      SDS Number: 10875044-00011      Date of last issue: 04.02.2025  
Date of first issue: 20.10.2022

Hygiene measures : Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Take care to prevent spills, waste and minimize release to the environment.  
If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers : Keep in properly labelled containers. Store locked up. Keep in a cool, well-ventilated place. Store in accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:  
Strong oxidizing agents  
Gases

### 7.3 Specific end use(s)

Specific use(s) : No data available

## SECTION 8: Exposure controls/personal protection

### 8.1 Control parameters

#### Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Propan-2-ol	67-63-0	TWA	100 ppm 245 mg/m <sup>3</sup>	FOR-2011-12-06-1358
Ivermectin	70288-86-7	TWA	30 µg/m <sup>3</sup> (OEB 3)	Internal
Further information: Skin				
		Wipe limit	300 µg/100 cm <sup>2</sup>	Internal

#### Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health effects	Value
7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-	Workers	Inhalation	Long-term systemic effects	0,18 mg/m <sup>3</sup>

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ivermectin (0.50%) Liquid Formulation

Version 6.0      Revision Date: 14.04.2025      SDS Number: 10875044-00011      Date of last issue: 04.02.2025  
Date of first issue: 20.10.2022

carboxylate				
	Workers	Inhalation	Long-term local effects	0,18 mg/m3
	Workers	Skin contact	Long-term systemic effects	0,05 mg/kg bw/day
Cetyl octanoate	Workers	Inhalation	Long-term systemic effects	6,01 mg/m3
	Workers	Inhalation	Acute systemic effects	18,029 mg/m3
	Workers	Skin contact	Long-term systemic effects	17,043 mg/kg bw/day
	Workers	Skin contact	Acute systemic effects	51,128 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	1,483 mg/m3
	Consumers	Inhalation	Acute systemic effects	4,448 mg/m3
	Consumers	Skin contact	Long-term systemic effects	8,52 mg/kg bw/day
	Consumers	Skin contact	Acute systemic effects	25,56 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	0,851 mg/kg bw/day
	Consumers	Ingestion	Acute systemic effects	2,554 mg/kg bw/day
Propan-2-ol	Workers	Inhalation	Long-term systemic effects	500 mg/m3
	Workers	Skin contact	Long-term systemic effects	888 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	89 mg/m3
	Consumers	Skin contact	Long-term systemic effects	319 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	26 mg/kg bw/day

### Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate	Fresh water	0,024 mg/l
	Freshwater - intermittent	0,24 mg/l
	Marine water	0,0024 mg/l
	Sewage treatment plant	19,5 mg/l
	Fresh water sediment	0,211 mg/kg dry weight (d.w.)
	Marine sediment	0,0211 mg/kg dry weight (d.w.)
	Soil	0,0282 mg/kg dry weight (d.w.)
Propan-2-ol	Fresh water	140,9 mg/l

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ivermectin (0.50%) Liquid Formulation

Version 6.0      Revision Date: 14.04.2025      SDS Number: 10875044-00011      Date of last issue: 04.02.2025  
Date of first issue: 20.10.2022

	Marine water	140,9 mg/l
	Intermittent use/release	140,9 mg/l
	Sewage treatment plant	2251 mg/l
	Fresh water sediment	552 mg/kg dry weight (d.w.)
	Marine sediment	552 mg/kg dry weight (d.w.)
	Soil	28 mg/kg dry weight (d.w.)
	Oral (Secondary Poisoning)	160 mg/kg food
Ivermectin	Fresh water	0,000004 mg/l
	Marine water	0,000004 mg/l

### 8.2 Exposure controls

#### Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

#### Personal protective equipment

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection	:	
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Filter should conform to NS EN 14387
Filter type	:	Organic vapour type (A)

## SECTION 9: Physical and chemical properties

### 9.1 Information on basic physical and chemical properties

Physical state : liquid



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ivermectin (0.50%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.02.2025
6.0	14.04.2025	10875044-00011	Date of first issue: 20.10.2022

---

Colour	:	clear
		Straw-coloured
Odour	:	characteristic
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Flash point	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
pH	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Vapour pressure	:	No data available
Relative density	:	No data available
Density	:	No data available
Relative vapour density	:	No data available
Particle characteristics		

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ivermectin (0.50%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.02.2025
6.0	14.04.2025	10875044-00011	Date of first issue: 20.10.2022

Particle size : Not applicable

### 9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

Molecular weight : No data available

## SECTION 10: Stability and reactivity

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

### 10.4 Conditions to avoid

Conditions to avoid : None known.

### 10.5 Incompatible materials

Materials to avoid : Oxidizing agents

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

## SECTION 11: Toxicological information

### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Product:

Acute oral toxicity : Acute toxicity estimate: > 2.000 mg/kg  
Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 2.000 mg/kg  
Method: Calculation method

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ivermectin (0.50%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.02.2025
6.0	14.04.2025	10875044-00011	Date of first issue: 20.10.2022

---

### Components:

#### **Propan-2-ol:**

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 25 mg/l  
Exposure time: 6 h  
Test atmosphere: vapour

Acute dermal toxicity : LD50 (Rabbit): > 5.000 mg/kg

#### **7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:**

Acute oral toxicity : LD50 (Rat, male): > 2.959 - 5.000 mg/kg  
Method: OECD Test Guideline 401

Acute inhalation toxicity : LC50 (Rat): >= 5,19 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Method: OECD Test Guideline 436  
Assessment: The substance or mixture has no acute inhalation toxicity

Acute dermal toxicity : LD50 (Rat): > 2.000 mg/kg  
Method: OECD Test Guideline 402  
Assessment: The substance or mixture has no acute dermal toxicity

#### **Ivermectin:**

Acute oral toxicity : LD50 (Rat): 50 mg/kg  
  
LD50 (Mouse): 25 mg/kg  
  
LD50 (Monkey): > 24 mg/kg  
Target Organs: Central nervous system  
Symptoms: Vomiting, Dilatation of the pupil  
Remarks: No mortality observed at this dose.

Acute inhalation toxicity : LC50 (Rat): 5,11 mg/l  
Exposure time: 1 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): 406 mg/kg  
  
LD50 (Rat): > 660 mg/kg

#### **Skin corrosion/irritation**

|| Not classified based on available information.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ivermectin (0.50%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.02.2025
6.0	14.04.2025	10875044-00011	Date of first issue: 20.10.2022

---

### Components:

#### **Propan-2-ol:**

Species	:	Rabbit
Result	:	No skin irritation

#### **7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:**

Species	:	Rabbit
Method	:	OECD Test Guideline 404
Result	:	No skin irritation

#### **Ivermectin:**

Species	:	Rabbit
Result	:	No skin irritation

### **Serious eye damage/eye irritation**

**||** Causes serious eye irritation.

### Components:

#### **Propan-2-ol:**

Species	:	Rabbit
Result	:	Irritation to eyes, reversing within 21 days

#### **7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:**

Species	:	Rabbit
Method	:	OECD Test Guideline 405
Result	:	No eye irritation

#### **Ivermectin:**

Species	:	Rabbit
Result	:	Mild eye irritation

### **Respiratory or skin sensitisation**

#### **Skin sensitisation**

**||** May cause an allergic skin reaction.

#### **Respiratory sensitisation**

**||** Not classified based on available information.

### Components:

#### **Propan-2-ol:**

Test Type	:	Buehler Test
Exposure routes	:	Skin contact
Species	:	Guinea pig
Method	:	OECD Test Guideline 406
Result	:	negative

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ivermectin (0.50%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.02.2025
6.0	14.04.2025	10875044-00011	Date of first issue: 20.10.2022

### 7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Test Type	: Maximisation Test
Exposure routes	: Skin contact
Species	: Guinea pig
Result	: positive
Assessment	: Probability or evidence of skin sensitisation in humans

### Ivermectin:

Exposure routes	: Dermal
Species	: Humans
Result	: Does not cause skin sensitisation.

### Germ cell mutagenicity

|| Suspected of causing genetic defects.

### Components:

#### Propan-2-ol:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative  Test Type: In vitro mammalian cell gene mutation test Result: negative
Genotoxicity in vivo	: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Result: negative

### 7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Method: OECD Test Guideline 471 Result: positive  Test Type: In vitro mammalian cell gene mutation test Result: positive  Test Type: In vitro sister chromatid exchange assay in mammalian cells Result: positive  Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro) Result: positive
Genotoxicity in vivo	: Test Type: Unscheduled DNA synthesis (UDS) test with mammalian liver cells in vivo Species: Rat Application Route: Ingestion

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ivermectin (0.50%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.02.2025
6.0	14.04.2025	10875044-00011	Date of first issue: 20.10.2022

---

Method: OECD Test Guideline 486  
Result: negative

Test Type: Micronucleus test  
Species: Mouse  
Application Route: Intraperitoneal injection  
Result: negative

Test Type: Transgenic rodent somatic cell gene mutation assay  
Species: Mouse  
Application Route: Ingestion  
Method: OECD Test Guideline 488  
Result: positive

Germ cell mutagenicity- Assessment : Positive result(s) from in vivo mammalian somatic cell mutagenicity tests.

### **Ivermectin:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)  
Test system: human diploid fibroblasts  
Result: negative

Test Type: Mouse Lymphoma  
Result: negative

### **Carcinogenicity**

|| Not classified based on available information.

### **Components:**

#### **Propan-2-ol:**

Species : Rat  
Application Route : inhalation (vapour)  
Exposure time : 104 weeks  
Method : OECD Test Guideline 451  
Result : negative

#### **7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:**

Species : Mouse  
Application Route : Skin contact  
Exposure time : 29 Months  
Result : negative

### **Ivermectin:**

Species : Rat

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ivermectin (0.50%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.02.2025
6.0	14.04.2025	10875044-00011	Date of first issue: 20.10.2022

Application Route : Oral  
NOAEL : 1,5 mg/kg body weight  
Result : negative  
Remarks : Based on data from similar materials

Species : Mouse  
Application Route : Oral  
NOAEL : 2,0 mg/kg body weight  
Result : negative  
Remarks : Based on data from similar materials

### Reproductive toxicity

|| Not classified based on available information.

#### Components:

##### **Propan-2-ol:**

Effects on fertility : Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative

##### **7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:**

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 414  
Result: negative

##### **Ivermectin:**

Effects on fertility : Test Type: Fertility  
Species: Rat  
Application Route: Oral  
Fertility: NOAEL: 0,6 mg/kg body weight  
Result: Animal testing did not show any effects on fertility.

Effects on foetal development : Test Type: Development  
Species: Mouse  
Application Route: Oral  
Developmental Toxicity: NOAEL: 0,2 mg/kg body weight  
Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Test Type: Development  
Species: Rat

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ivermectin (0.50%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.02.2025
6.0	14.04.2025	10875044-00011	Date of first issue: 20.10.2022

Application Route: Oral  
Developmental Toxicity: LOAEL: 0,4 mg/kg body weight  
Result: Embryotoxic effects and adverse effects on the offspring were detected.  
Remarks: The mechanism or mode of action may not be relevant in humans.

Test Type: Development  
Species: Rabbit  
Application Route: Oral  
Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

### STOT - single exposure

|| May cause drowsiness or dizziness.

#### Components:

##### **Propan-2-ol:**

Assessment : May cause drowsiness or dizziness.

##### **Ivermectin:**

Target Organs : Central nervous system  
Assessment : Causes damage to organs.

### STOT - repeated exposure

|| Not classified based on available information.

#### Components:

##### **7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:**

Exposure routes : Ingestion  
Target Organs : nasal cavity  
Assessment : Shown to produce significant health effects in animals at concentrations of >10 to 100 mg/kg bw.

##### **Ivermectin:**

Target Organs : Central nervous system  
Assessment : Causes damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

#### Components:

##### **Propan-2-ol:**

Species : Rat  
NOAEL : 12,5 mg/l  
Application Route : inhalation (vapour)  
Exposure time : 104 Weeks



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ivermectin (0.50%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.02.2025
6.0	14.04.2025	10875044-00011	Date of first issue: 20.10.2022

---

### 7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Species	: Rat
NOAEL	: 5 mg/kg
LOAEL	: 50 mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days
Method	: OECD Test Guideline 408

### Ivermectin:

Species	: Dog
NOAEL	: 0,5 mg/kg
LOAEL	: 1 mg/kg
Application Route	: Oral
Exposure time	: 14 Weeks
Target Organs	: Central nervous system
Symptoms	: Dilatation of the pupil, Tremors, Lack of coordination, anorexia

Species	: Monkey
NOAEL	: 1,2 mg/kg
Application Route	: Oral
Exposure time	: 2 Weeks
Remarks	: No significant adverse effects were reported

Species	: Rat
NOAEL	: 0,4 mg/kg
LOAEL	: 0,8 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: spleen, Bone marrow, Kidney

### Aspiration toxicity

|| Not classified based on available information.

## 11.2 Information on other hazards

### Endocrine disrupting properties

|| Not classified based on available information.

### Product:

Assessment	: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
------------	---

### Experience with human exposure

### Components:

### Ivermectin:

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ivermectin (0.50%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.02.2025
6.0	14.04.2025	10875044-00011	Date of first issue: 20.10.2022

Skin contact	:	Remarks: Can be absorbed through skin.
Eye contact	:	Remarks: May irritate eyes.
Ingestion	:	Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vomiting, anorexia, Lack of coordination

### SECTION 12: Ecological information

#### 12.1 Toxicity

##### Components:

##### **Propan-2-ol:**

Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): 9.640 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 10.000 mg/l Exposure time: 24 h
Toxicity to microorganisms	:	EC50 (Pseudomonas putida): > 1.050 mg/l Exposure time: 16 h

##### **7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:**

Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): 24 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 40 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	:	ErC50 (Raphidocelis subcapitata (freshwater green alga)): > 110 mg/l Exposure time: 72 h Method: OECD Test Guideline 201  NOEC (Raphidocelis subcapitata (freshwater green alga)): 30 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to microorganisms	:	EC10 (activated sludge): 409 mg/l Exposure time: 3 h Method: OECD Test Guideline 209

##### **Ivermectin:**

Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): 0,003 mg/l Exposure time: 96 h  LC50 (Lepomis macrochirus (Bluegill sunfish)): 0,0048 mg/l Exposure time: 96 h
------------------	---	--

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ivermectin (0.50%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.02.2025
6.0	14.04.2025	10875044-00011	Date of first issue: 20.10.2022

Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 0,000025 mg/l Exposure time: 48 h
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 9,1 mg/l Exposure time: 72 h Method: OECD Test Guideline 201  NOEC (Pseudokirchneriella subcapitata (green algae)): 9,1 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
M-Factor (Acute aquatic toxicity)	:	10.000
M-Factor (Chronic aquatic toxicity)	:	10.000

### 12.2 Persistence and degradability

#### Components:

##### **Propan-2-ol:**

Biodegradability	:	Result: rapidly degradable
BOD/COD	:	BOD: 1,19 (BOD5) COD: 2,23 BOD/COD: 53 %

##### **7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:**

Biodegradability	:	Result: Not readily biodegradable. Biodegradation: 71 % Exposure time: 28 d Method: OECD Test Guideline 301B
------------------	---	---

##### **Ivermectin:**

Biodegradability	:	Result: Not readily biodegradable. Biodegradation: 50 % Exposure time: 240 d
------------------	---	--

### 12.3 Bioaccumulative potential

#### Components:

##### **Propan-2-ol:**

Partition coefficient: n-octanol/water	:	log Pow: 0,05
--	---	---------------

##### **7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:**

Partition coefficient: n-octanol/water	:	log Pow: 1,34 Method: OECD Test Guideline 107
--	---	--

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ivermectin (0.50%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.02.2025
6.0	14.04.2025	10875044-00011	Date of first issue: 20.10.2022

---

### Ivermectin:

Bioaccumulation : Bioconcentration factor (BCF): 74

Partition coefficient: n-octanol/water : log Pow: 3,22

### 12.4 Mobility in soil

No data available

### 12.5 Results of PBT and vPvB assessment

#### Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

### 12.6 Endocrine disrupting properties

#### Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### 12.7 Other adverse effects

No data available

---

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

Product	: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

---

## SECTION 14: Transport information

### 14.1 UN number or ID number

ADN	: UN 3082
ADR	: UN 3082

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ivermectin (0.50%) Liquid Formulation

Version 6.0	Revision Date: 14.04.2025	SDS Number: 10875044-00011	Date of last issue: 04.02.2025 Date of first issue: 20.10.2022
----------------	------------------------------	-------------------------------	---

**RID** : UN 3082

**IMDG** : UN 3082

**IATA** : UN 3082

### 14.2 UN proper shipping name

**ADN** : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,  
N.O.S.  
(Ivermectin)

**ADR** : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,  
N.O.S.  
(Ivermectin)

**RID** : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,  
N.O.S.  
(Ivermectin)

**IMDG** : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,  
N.O.S.  
(Ivermectin)

**IATA** : Environmentally hazardous substance, liquid, n.o.s.  
(Ivermectin)

### 14.3 Transport hazard class(es)

	Class	Subsidiary risks
<b>ADN</b>	: 9	
<b>ADR</b>	: 9	
<b>RID</b>	: 9	
<b>IMDG</b>	: 9	
<b>IATA</b>	: 9	

### 14.4 Packing group

**ADN**  
Packing group : III  
Classification Code : M6  
Hazard Identification Number : 90  
Labels : 9

**ADR**  
Packing group : III  
Classification Code : M6  
Hazard Identification Number : 90  
Labels : 9  
Tunnel restriction code : (-)

**RID**  
Packing group : III  
Classification Code : M6  
Hazard Identification Number : 90  
Labels : 9

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ivermectin (0.50%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.02.2025
6.0	14.04.2025	10875044-00011	Date of first issue: 20.10.2022

### IMDG

Packing group : III  
Labels : 9  
EmS Code : F-A, S-F

### IATA (Cargo)

Packing instruction (cargo aircraft) : 964  
Packing instruction (LQ) : Y964  
Packing group : III  
Labels : Miscellaneous

### IATA (Passenger)

Packing instruction (passenger aircraft) : 964  
Packing instruction (LQ) : Y964  
Packing group : III  
Labels : Miscellaneous

## 14.5 Environmental hazards

### ADN

Environmentally hazardous : yes

### ADR

Environmentally hazardous : yes

### RID

Environmentally hazardous : yes

### IMDG

Marine pollutant : yes

### IATA (Passenger)

Environmentally hazardous : yes

### IATA (Cargo)

Environmentally hazardous : yes

## 14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

## 14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

## SECTION 15: Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) : Conditions of restriction for the following entries should be considered: Number on list 3  
||REACH - Restrictions on the manufacture, placing on

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ivermectin (0.50%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.02.2025
6.0	14.04.2025	10875044-00011	Date of first issue: 20.10.2022

the market and use of certain dangerous substances,  
mixtures and articles (Annex XVII)

Number on list 75: If you intend to  
use this product as tattoo ink, please  
contact your vendor.

REACH - Restrictions on the manufacture, placing on  
the market and use of certain dangerous substances,  
mixtures and articles (Annex XVII)

Substance(s) or mixture(s) are listed  
here according to their appearance  
in the regulation, irrespective of their  
use/purpose or the conditions of the  
restriction. Please refer to the condi-  
tions in corresponding Regulation to  
determine whether an entry is appli-  
cable to the placing on the market or  
not.

REACH - Candidate List of Substances of Very High  
Concern for Authorisation (Article 59). : Not applicable

REACH - List of substances subject to authorisation  
(Annex XIV) : Not applicable

Regulation (EU) No 2024/590 on substances that de-  
plete the ozone layer : Not applicable

Regulation (EU) 2019/1021 on persistent organic pollu-  
tants (recast) : Not applicable

Regulation (EU) No 649/2012 of the European Parlia-  
ment and the Council concerning the export and import  
of dangerous chemicals : Not applicable

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of  
major-accident hazards involving dangerous substances.

E1	ENVIRONMENTAL HAZARDS	Quantity 1 100 t	Quantity 2 200 t
----	--------------------------	---------------------	---------------------

### Other regulations:

Note the Working Environment Act § 4-1 and § 4-2 on requirements for the employer to protect  
pregnant employees against discomfort and injury as a result of the work situation and the  
working environment.

Note the regulation on organization, leadership and participation, chapter 12 on the work of  
children and young people.

### The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

## SECTION 16: Other information

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ivermectin (0.50%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.02.2025
6.0	14.04.2025	10875044-00011	Date of first issue: 20.10.2022

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

### Full text of H-Statements

H225	: Highly flammable liquid and vapour.
H300	: Fatal if swallowed.
H311	: Toxic in contact with skin.
H317	: May cause an allergic skin reaction.
H319	: Causes serious eye irritation.
H336	: May cause drowsiness or dizziness.
H341	: Suspected of causing genetic defects.
H370	: Causes damage to organs if swallowed.
H372	: Causes damage to organs through prolonged or repeated exposure if swallowed.
H373	: May cause damage to organs through prolonged or repeated exposure.
H400	: Very toxic to aquatic life.
H410	: Very toxic to aquatic life with long lasting effects.
H412	: Harmful to aquatic life with long lasting effects.

### Full text of other abbreviations

Acute Tox.	: Acute toxicity
Aquatic Acute	: Short-term (acute) aquatic hazard
Aquatic Chronic	: Long-term (chronic) aquatic hazard
Eye Irrit.	: Eye irritation
Flam. Liq.	: Flammable liquids
Muta.	: Germ cell mutagenicity
Skin Sens.	: Skin sensitisation
STOT RE	: Specific target organ toxicity - repeated exposure
STOT SE	: Specific target organ toxicity - single exposure
FOR-2011-12-06-1358	: Norway. Occupational Exposure limits
FOR-2011-12-06-1358 / TWA	: Long term exposure limit

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - Interna-



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Ivermectin (0.50%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.02.2025
6.0	14.04.2025	10875044-00011	Date of first issue: 20.10.2022

tional Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

### Classification of the mixture:

Eye Irrit. 2	H319
Skin Sens. 1	H317
Muta. 2	H341
STOT SE 3	H336
Aquatic Acute 1	H400
Aquatic Chronic 1	H410

### Classification procedure:

Calculation method
Calculation method
Calculation method
Calculation method
Calculation method
Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN